NewAmsterdam Pharma names new accounting officer, details COO exit terms

NewAmsterdam Pharma Company N.V. disclosed two personnel matters in filings dated August 14, 2026.

On August 10, 2026, the company appointed Robert W. Gunning, age 55, as its principal accounting officer.¹ He takes over the role from Louise Kooij, who is set to leave the company on August 31, 2026, a departure the company had already disclosed.¹ Gunning had joined the company as Vice President, Controller on the same date, August 10, 2026.¹ His prior roles included serving as Interim Controller and a consultant on financial and accounting matters to Altimmune, Inc. from April 2026 to July 2026¹, and holding the position of Vice President Finance and Corporate Controller at Y-mAbs Therapeutics, Inc. from April 2022 to April 2026, before that company was acquired by SERB Pharmaceuticals.¹

Under his offer letter dated July 24, 2026, Gunning's base salary will be $375,000 per year, with eligibility for an annual performance bonus targeted at 30% of base salary, prorated for his first partial year and subject to board discretion.¹ He will also receive a restricted stock unit award for 3,200 ordinary shares and a stock option to purchase 14,000 ordinary shares under the company's 2024 Inducement Plan.¹

Separately, an amended 8-K provided details on the exit of Douglas Kling, who resigned as Chief Operating Officer effective August 14, 2026, to become CEO of another clinical-stage biotech company.² Under his separation agreement, unvested equity awards were forfeited except for a portion tied solely to continued service through May 14, 2027, which will keep vesting as long as Kling provides services under a separate advisor agreement.² That advisor agreement covers work on the "PREVAIL" trial of obicetrapib and other programs², in exchange for a $50,000 monthly fee plus expenses, and is set to expire on May 14, 2027 unless ended earlier under its terms.²